Status: Recruiting
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Participants needed: 26
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: PanTher TherapeuticsUpdated: May 20, 2026Locations: 6
Eligibility criteria
Imaging consistent with primary borderline resectable or locally advanced PDAC.... [+8]
Active non-pancreatic cancer that currently requires treatment or is being treat... [+7]